Indications for Serotypes A and B Botulinum Toxins

April 16th, 2018 - Find-A-Code
Categories:   HCPCS Coding   Medicare   Drugs|Pharmaceuticals|FDA  
0 Votes - Sign in to vote or comment.

According to Novitas LCD L27476, the following indications apply:

1. Blepharospasm and strabismus

2. Spastic dystonia or focal dystonias to relieve pain, to assist posturing and walking, to increase range of motion, to assist in the outcome of physical therapy, and/or to reduce spasm thus allowing adequate perineal hygiene.

3. Spasmodic dysphonia

4. Achalasia and cardiospasm when at least one of the following conditions is met:

  • Patient has failed conventional therapy or has a contraindication to such therapy
  • Patient is at high risk of complications from pneumatic dilation or surgical myotomy
  • Prior myotomy or dilation has failed
  • Prior dilation-induced esophageal perforation
  • Patient has an epiphrenic diverticulum or hiatal hernia

5. Severe primary focal hyperhidrosis in patients who are not adequately managed with topical agents or ionotophoresis (or have a contraindication to such treatment), and who manifest all of the following indications:

  • Severe sweating beyond physiological needs
  • Focal, visible, severe sweating of at least 6 months duration without apparent cause with at least 2 of the following characteristics:

    – Bilateral and relatively symmetric
    – Significant impairment in daily activities
    – Age of onset less than 25 years
    – Positive family history
    – Cessation of focal sweating during sleep

6. Disability from sialorrhea due to conditions such as motor neuron disease or Parkinson’s disease in those patients who have failed to respond to a reasonable trial of traditional therapies (i.e., anticholinergics, speech therapy, surgical therapy), or who have a contraindication to traditional therapy.

7. OnabotulinumtoxinA, serotype A botulinum toxin, can be used to treat urinary incontinence due to neurogenic bladder or bladder over-activity. This treatment will be considered reasonable and necessary if used only after documented failure of medical therapy.

8. OnabotulinumtoxinA, serotype A botulinum toxin is considered reasonable and necessary for prophlaxis/treatment of headaches in adult patients with chronic intractable migraine more than 15 days/month, with headache lasting 4 hours a day or longer.

The determination regarding whether serotypes A or B botulinum toxin is the most appropriate course of treatment should be based on the physician’s judgment, clinical experience, and the patient’s individual history. If the clinical use of the drug is not an FDA approved use for the specific botulinum toxin product, peer-reviewed medical literature supporting that use should be kept on file and the claim should be submitted with a KX modifier. The KX modifier should not be used for diagnoses that are specifically noted as not reasonable and necessary in this drug policy. See the article: “Approved Drugs and Biologicals; Includes Cancer Chemotherapeutic Agents” (A47797) for further details.

Electrical Stimulation for chemodenervation or electromyography procedure(s) may be medically necessary when the proper injection site(s) are difficult to determine.

###

Questions, comments?

If you have questions or comments about this article please contact us.  Comments that provide additional related information may be added here by our Editors.


Latest articles:  (any category)

How to Combat COVID-Related Risk Adjustment Losses with the Medicare Annual Wellness Exam
April 12th, 2021 - Aimee Wilcox, CPMA, CCS-P, CST, MA, MT, Director of Content
Identifying new ways to encourage Medicare beneficiaries to schedule and attend their Annual Wellness Exam (AWE) can be difficult, but the Open Enrollment period is a prime time for every payer to identify new beneficiaries and provide a reminder to both new and existing patients that this preventive service does ...
Failure to Follow Payer’s Clinical Staff Rules Costs Provider $273K
April 12th, 2021 - Wyn Staheli, Director of Research
Clinical staff (e.g., LPN, RN, MA) provide essential services which allow providers to leverage their time and improve reimbursement opportunities and run their practices more efficiently. There is, however, an ongoing question of how to appropriately bill for clinical staff time. This is really a complex question which comes down to code descriptions, federal or state licensure, AND payer policies. Failure to understand licensing and payer policies led a Connecticut provider organization down a path that ended in a $273,000 settlement with both federal and state governments.
Properly Reporting Imaging Overreads (Including X-Rays)
April 8th, 2021 - Aimee Wilcox CPMA, CCS-P, CST, MA, MT and Wyn Staheli, Director of Content Research
hile many provider groups offer some imaging services in their offices, others may rely on external imaging centers. When the provider reviews images performed by an external source (e.g., independent imaging center), that is typically referred to as an overread or a re-read. Properly reporting that work depends on a variety of factors as discussed in this article.
How Social Determinants of Health (SDOH) Data Enhances Risk Adjustment
March 31st, 2021 - Aimee Wilcox, CPMA, CCS-P, CST, MA, MT, Director of Content
The role of SDOH in overall patient care and outcomes has become a more common topic of discussion among healthcare providers, payers, and policymakers alike. All are attempting to identify and collect SDOH and correlate the data to patient management which is increasingly seen as necessary to address certain health disparities and identify exactly how SDOH affects patient health outcomes. Learn how to address this important subject.
Understanding Skin Biopsy Codes
March 23rd, 2021 - Christine Woolstenhulme, QCC, QMCS, CPC, CMRS
A biopsy is a procedure to obtain only a portion of a lesion for a pathologic exam. According to the AMA, "The use of a biopsy procedure code (e.g., 11102, 11103) indicates that the procedure to obtain tissue for pathologic examination was performed independently, or was unrelated or distinct from other ...
How Reporting E/M Based on Time May Lose Money
March 18th, 2021 - Aimee Wilcox, CPMA, CCS-P, CST, MA, MT, Director of Content
Just like math teachers who require students to show their work so they can see how the student reached their answer, providers are also required to "show their work" through the documentation process in the medical record. By the time a provider has reviewed the patient's subjective complaints (i.e., patient's ...
COVID-19 Vaccines
March 10th, 2021 - Christine Woolstenhulme, QCC, QMCS, CPC, CMRS
To accommodate the new COVID-19 immunizations the CPT editorial panel has approved 11 Category I codes. Watch for new and revised guidelines and parenthetical notes with these codes. For example; which administration codes should be used with the vaccine codes and the NCD codes applicable to the dose being administered. These ...



Home About Contact Terms Privacy

innoviHealth® - 62 E 300 North, Spanish Fork, UT 84660 - Phone 801-770-4203 (9-5 Mountain)

Copyright © 2000-2021 innoviHealth Systems®, Inc. - CPT® copyright American Medical Association